News Release(2018)

2018
-
November 27, 2018
Launch of "P-TOL® Granules" for the Treatment of Hyperphosphatemia
-
November 20, 2018
Launch of "Beova® Tablets 50mg" for the Treatment of Overactive Bladder
-
October 30, 2018
Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib
-
September 21, 2018
Kyorin Receives Marketing Approval in Japan for "Beova® Tablets 50mg" for the Treatment of Overactive Bladder
-
May 30, 2018
Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia
-
April 23, 2018
Kissei Announces New President and COO
-
January 17, 2018
JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study